SanegeneBio Partners with Eli Lilly in $1.2 Billion RNAi Metabolic Disease Collaboration

SanegeneBio, a clinical-stage biotechnology company focused on RNAi therapeutics, has entered a global research and licensing collaboration with Eli Lilly and Company to develop RNAi-based treatments for metabolic diseases.

The partnership will leverage SanegeneBio’s proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) platform, designed for tissue-selective RNAi delivery that enables therapies requiring dosing as infrequently as twice a year.

Under the agreement, SanegeneBio will lead the discovery and optimization of LEAD™-based RNAi molecules, while Lilly will handle preclinical, clinical, and commercial development.

“Partnering with Lilly represents a strong validation of our LEAD™ platform,” said Dr. Weimin Wang, CEO and Founder of SanegeneBio. “Together, we aim to advance durable, disease-modifying therapies for patients with metabolic disorders worldwide.”

SanegeneBio will receive an upfront payment, an equity investment, and near-term milestone payments, with potential total payments of up to $1.2 billion tied to discovery, development, regulatory, and commercial milestones, plus tiered royalties on future sales.